JP5753541B2 - 抗ｖｅｇｆ治療によって治療された患者におけるタンパク尿の初期マーカー - Google Patents

抗ｖｅｇｆ治療によって治療された患者におけるタンパク尿の初期マーカー Download PDF

Info

Publication number
JP5753541B2
JP5753541B2 JP2012546149A JP2012546149A JP5753541B2 JP 5753541 B2 JP5753541 B2 JP 5753541B2 JP 2012546149 A JP2012546149 A JP 2012546149A JP 2012546149 A JP2012546149 A JP 2012546149A JP 5753541 B2 JP5753541 B2 JP 5753541B2
Authority
JP
Japan
Prior art keywords
epithelial cells
glomerular epithelial
therapy
urinary
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012546149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515268A (ja
JP2013515268A5 (https=
Inventor
ベスナ ディー． ガロビック
ベスナ ディー． ガロビック
Original Assignee
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ filed Critical メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ
Publication of JP2013515268A publication Critical patent/JP2013515268A/ja
Publication of JP2013515268A5 publication Critical patent/JP2013515268A5/ja
Application granted granted Critical
Publication of JP5753541B2 publication Critical patent/JP5753541B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2012546149A 2009-12-21 2010-12-21 抗ｖｅｇｆ治療によって治療された患者におけるタンパク尿の初期マーカー Expired - Fee Related JP5753541B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28851409P 2009-12-21 2009-12-21
US61/288,514 2009-12-21
PCT/US2010/061543 WO2011084791A2 (en) 2009-12-21 2010-12-21 Early marker of proteinuria in patients treated with an anti-vegf treatment

Publications (3)

Publication Number Publication Date
JP2013515268A JP2013515268A (ja) 2013-05-02
JP2013515268A5 JP2013515268A5 (https=) 2014-02-06
JP5753541B2 true JP5753541B2 (ja) 2015-07-22

Family

ID=44306097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012546149A Expired - Fee Related JP5753541B2 (ja) 2009-12-21 2010-12-21 抗ｖｅｇｆ治療によって治療された患者におけるタンパク尿の初期マーカー

Country Status (8)

Country Link
US (4) US20130034861A1 (https=)
EP (1) EP2517014B1 (https=)
JP (1) JP5753541B2 (https=)
AU (1) AU2010339723B2 (https=)
BR (1) BR112012017767A2 (https=)
CA (1) CA2785273A1 (https=)
ES (1) ES2530866T3 (https=)
WO (1) WO2011084791A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
US20130034861A1 (en) 2009-12-21 2013-02-07 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
WO2014104019A1 (ja) * 2012-12-26 2014-07-03 デンカ生研株式会社 尿中ポドサイトの検出方法
WO2021055089A1 (en) * 2019-09-20 2021-03-25 The University Of North Carolina At Chapel Hill Methods of identifying risk of bevacizumab-induced proteinuria and hypertension

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9306053D0 (en) 1993-03-24 1993-05-12 Nycomed Pharma As Method and assay
WO2002037099A1 (en) 2000-10-27 2002-05-10 International Reagents Corporation Method of diagnosing nephropathy
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
WO2003075016A1 (en) 2002-03-07 2003-09-12 Cambridge University Technical Services Limited (Cuts) Scd fingerprints
US20030198959A1 (en) * 2002-03-28 2003-10-23 Kurnit David M. Methods and compositions for analysis of urine samples in the diagnosis and treatment of kidney diseases
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
JP2007532913A (ja) 2004-04-16 2007-11-15 ユニバーシティー オブ マサチューセッツ 細胞内病原体の検出法および定量化法
EP1786477A2 (en) * 2004-08-17 2007-05-23 Prolx Pharmaceuticals Corp. Method of preselection patients for anti-vegf, anti-hif-1 or anti-thioredoxin therapy
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
WO2008075173A2 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders
EP2146728A4 (en) 2007-05-21 2010-12-29 Univ Wake Forest Health Sciences PROGENITOR CELLS FROM URINE AND METHODS FOR THEIR USE
US20090068683A1 (en) 2007-06-11 2009-03-12 Mayo Foundation For Medical Education And Research Markers for preeclampsia
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
CN101970486A (zh) * 2007-10-25 2011-02-09 布里斯托尔大学 特异于血管内皮生长因子(vegf)的促血管发生同工型的抗体
WO2010065968A1 (en) 2008-12-05 2010-06-10 Myriad Genetics, Inc. Cancer detection markers
US20120164667A1 (en) 2009-06-10 2012-06-28 Masanori Hara Method for test on diabetic nephropathy
US20130034861A1 (en) 2009-12-21 2013-02-07 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
TWI762890B (zh) 2010-05-12 2022-05-01 開曼群島商英瑞金公司 生物活性腎細胞
AU2013267139B2 (en) 2012-06-01 2018-11-01 Mayo Foundation For Medical Education And Research High-throughput early detection and point-of-care early detection of pregnant women susceptible to developing preeclampsia
WO2014055687A1 (en) 2012-10-05 2014-04-10 Hitachi Chemical Co., Ltd. Urine exosome mrnas and methods of using same to detect diabetic nephropathy
US20170003299A1 (en) 2013-11-27 2017-01-05 Mayo Foundation For Medical Education And Research Detecting podocyte injury in diabetic nephropathy and glomerulonephritis

Also Published As

Publication number Publication date
US10336822B2 (en) 2019-07-02
JP2013515268A (ja) 2013-05-02
WO2011084791A3 (en) 2011-11-24
EP2517014A4 (en) 2013-07-17
EP2517014B1 (en) 2014-11-19
US20160060333A1 (en) 2016-03-03
US20180002416A1 (en) 2018-01-04
US9213038B2 (en) 2015-12-15
US20130296397A1 (en) 2013-11-07
AU2010339723A1 (en) 2012-08-09
US9765137B2 (en) 2017-09-19
AU2010339723B2 (en) 2014-11-06
BR112012017767A2 (pt) 2019-09-24
ES2530866T3 (es) 2015-03-06
WO2011084791A2 (en) 2011-07-14
US20130034861A1 (en) 2013-02-07
CA2785273A1 (en) 2011-07-14
EP2517014A2 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
CA2947932C (en) Pd-l1 antibodies and uses thereof
Nurbhai et al. Oral anti-tumour necrosis factor domain antibody V565 provides high intestinal concentrations, and reduces markers of inflammation in ulcerative colitis patients
Wu et al. Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression
ES2791950T3 (es) Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1)
Jayachandran et al. Extracellular vesicles in urine of women with but not without kidney stones manifest patterns similar to men: a case control study
AU2018272054A1 (en) Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
US10336822B2 (en) Early marker of proteinuria in patients treated with an anti-VEGF treatment
CA2760569A1 (en) New antibody cocktail
Moe et al. Association of hepatitis C virus infection with prevalence and development of kidney disease
van Schouwenburg et al. Using monoclonal antibodies as an international standard for the measurement of anti-adalimumab antibodies
US20100015643A1 (en) Method of quantitative determination of antigen protein and quantitative determination kit therefor
Lomonte et al. Sestamibi scintigraphy, topography, and histopathology of parathyroid glands in secondary hyperparathyroidism
EP2841593B1 (en) Clostridium difficile dehydrogenase and toxin as a biomarker
US20230285394A1 (en) Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
Gescher et al. A priori implantation potential does not differ in eutopic endometrium of patients with and without endometriosis
Wasilewska et al. Urinary OPN excretion in children with glomerular proteinuria
EP4348261A1 (en) Fibrosis biomarkers for non-alcoholic fatty liver disease
JP2021089221A (ja) 前がん病変の検出方法及び前がん病変か否かの診断を補助する方法
US20070166774A1 (en) Functional immunoassay
WO2013086637A1 (en) Lamin a/c and prelamins as indicators of frailty and vulnerability or resiliency to adverse health outcomes
Caicedo et al. Establishing clinically meaningful ranges of metal hypersensitivity in orthopaedic patients using COVID-19 vaccine-induced adaptive immune responses from fully vaccinated adults
WO2025005258A1 (ja) 急性膵炎における膵炎マーカーの迅速測定法
Torres Method Comparison Study of Two Commercially Available Tests for the Measurement of Ustekinumab Levels
WO2026085565A1 (en) Antigen-binding molecules and uses thereof
Muñoz-Villafranca et al. Infliximab and Adalimumab Monitoring versus Clinical Control during Maintenance Therapy in Randomized Patients with Inflammatory Bowel Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140723

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150522

R150 Certificate of patent or registration of utility model

Ref document number: 5753541

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees